Related Experiment Video
Updated: Apr 26, 2026
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice
Luis Solans1, Santiago Uranga1, Nacho Aguilo1
1Grupo de Genética de Micobacterias, Dpto. Microbiología, Medicina Preventiva y Salud Pública, Facultad de Medicina, Universidad de Zaragoza, C/Domingo Miral s/n, 50009 Zaragoza, Spain; CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain.
A new tuberculosis vaccine candidate, MTBVAC erp(-), shows enhanced safety and efficacy. This highly attenuated live vaccine is a promising option for immune-compromised individuals, unlike the current BCG vaccine.
Area of Science:
- * Immunology
- * Vaccinology
- * Microbiology
Background:
- * Live vaccines require careful safety assessment in immunocompromised individuals.
- * Mycobacterium bovis BCG is the only licensed tuberculosis vaccine but has safety concerns.
- * MTBVAC is a promising next-generation tuberculosis vaccine candidate with demonstrated safety and superior protection in mice compared to BCG.
Purpose of the Study:
- * To develop a hyper-attenuated MTBVAC-based vaccine (MTBVAC erp(-)) for improved safety in immune-suppressed populations.
- * To evaluate the safety and protective efficacy of MTBVAC erp(-) in animal models.
- * To assess its potential as a tuberculosis vaccine for high-risk groups.
Main Methods:
- * Genetic engineering of MTBVAC by inactivating the erp virulence gene.
- * Testing the attenuated strain MTBVAC erp(-) in severe combined immunodeficiency (SCID) mice.
- * Evaluating MTBVAC erp(-) in immunocompetent mice to compare protective efficacy with BCG.
Main Results:
- * MTBVAC erp(-) demonstrated severe attenuation in SCID mice compared to BCG and MTBVAC.
- * The hyper-attenuated MTBVAC erp(-) maintained protective efficacy comparable to BCG in immunocompetent mice.
- * The genetic modification did not compromise the vaccine's ability to induce protection.
Conclusions:
- * MTBVAC erp(-) is a highly attenuated live vaccine candidate for tuberculosis.
- * Its enhanced safety profile makes it suitable for immune-compromised individuals.
- * MTBVAC erp(-) represents a potential alternative to BCG for high-risk populations, including those with HIV.
